# Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma

> **NCT00003501** · PHASE2 · TERMINATED · sponsor: **Burzynski Research Institute** · enrollment: 2 (actual)

## Conditions studied

- Non-hodgkins Lymphoma

## Interventions

- **DRUG:** Antineoplaston therapy (Atengenal + Astugenal)

## Key facts

- **NCT ID:** NCT00003501
- **Lead sponsor:** Burzynski Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1996-04-10
- **Primary completion:** 2003-07-02
- **Final completion:** 2003-07-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003501, "Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00003501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*